Gerresheimer: On the path to sustainable profitable growth
One documentmore
Stories about Injection (medicine)
Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy
moreGerresheimer on track for strong second half-year
moreGerresheimer on track for strong second half-year
One documentmoreMerck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis
moreSTADA expands specialty footprint through acquisition of innovative therapy for treating advanced Parkinson's disease
One documentmoreMerck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis
moreNorgine; AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand
moreGerresheimer with strong second quarter
One documentmoreAnnual General Meeting of Gerresheimer AG Approves Dividend Increase to EUR 1.20 per Share
moreAnnual General Meeting of Gerresheimer AG approves dividend increase to EUR 1.20 per share
One documentmoreInvestigational, Once-weekly Insulin Icodec Showed Comparable Efficacy and Safety to Once-daily Insulin Glargine U100 in Phase 2 Trial
moreSwitching to Ozempic® from another GLP-1 RA significantly reduced blood sugar and weight in people with type 2 diabetes in routine clinical practice
moreDebiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer
moreSaxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity
moreSenzer's Medical Device Approved in Europe for the Safe and Effective Delivery of Cannabinoids
moreMerck to Showcase New Data Across MS Portfolio at EAN 2019
moreMerck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
moreGerresheimer makes good start into the new financial year
One documentmoreOzempic® Superior in Lowering Blood Sugar and Weight Vs Placebo, Both in Combination with SGLT-2 Inhibitors
moreTechnische Universität München
Test predicts outcome of hay fever therapies
moreGerresheimer Increases Revenues by 8.8% and Successfully Integrates Sensile Medical
moreGerresheimer increases revenues by 8.8% and successfully integrates Sensile Medical
One documentmoreNew Phase 2 Data for Somapacitan Demonstrate Its Potential as an Efficacious Once-weekly Treatment for Childhood Growth Hormone Deficiency
moreKyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome
more
1